Irbesartan Recall Lawsuit

In October 2018, the FDA recalled Irbesartan after finding the probable human carcinogen N-nitrosodiethylamine (NDEA) had contaminated the drug. The impurity may cause tumors in various organs, including the liver, intestines, prostate, colon, and stomach. This recall follows the Valsartan recall in July 2018. This contamination and recall of these “Sartan” drugs is the largest in FDA history.

Irbesartan Recall Lawsuit: Case Quick Facts

The Problem: Irbesartan and Cancer

Irbesartan is an angiotensin receptor blocker (ARB) prescribed to treat high blood pressure and kidney disease in patients with type 2 diabetes and high blood pressure. The brand name, Avapro, was approved by the FDA in 1997, while the generic, Irbesartan, was approved on March 30, 2012. A Valsartan recall in July 2018 prompted the FDA to investigate all ARBs for impurities. This led the FDA to find that the NDEA impurity had tainted Irbesartan.

The Injuries: Side Effects of Irbesartan

According to the Environmental Protection Agency, exposure to NDEA can lead to:

Liver Cancer
Stomach Cancer
Colon Cancer
Intestinal Cancer
Prostate Cancer
Lower Esophageal Cancer
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Leukemia
Pancreatic Cancer

The Defendant(s)

The recalled Irbesartan was manufactured by Aurobindo Pharma Limited. This company supplied Irbesartan to:

ScieGen Pharmaceuticals labeled as Westminster Pharmaceuticals
ScieGen Pharmaceuticals labeled as Golden State Medical Supply, Inc.

There are several other manufacturers of Irbesartan, including Teva Pharmaceuticals and Hetero Labs Limited. Not all Irbesartan is recalled, so if you are concerned that your medication was contaminated, contact your doctor.

GoldenbergLaw Can Help

If you or a loved one took Irbesartan and was diagnosed with cancer, contact us.

Do I Qualify?

Free Consultations

Contact GoldenbergLaw today for a free consultation. Our consultations cost you nothing, including an obligation. The only time you’ll get a fee from us is if we win your case. Get your free consultation today and get started on your path towards justice and compensation.

FDA Irbesartan Recall – October 26, 2018

The FDA issued a recall for certain lots of Irbesartan. These lots were allegedly contaminated with NDEA.

Why Choose GoldenbergLaw?

GoldenbergLaw has over 30 years of experience and has recovered over $100 million in verdicts and settlements. We have the passion and resources to help you out. Don’t wait. Contact us, and leave the sleepless nights to us.